The US Food and Drug Administration (FDA) has granted approval to France-based Sanofi Pasteur for its Dengvaxia vaccine intended for the prevention of dengue disease in endemic regions, it was reported yesterday.
The product is said to be the first US FDA-approved vaccine to prevent dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people aged between 9 and 16 years who have laboratory-confirmed previous dengue infection and who live in endemic areas. It is a live and attenuated vaccine, which is administered as three separate injections. Initial dose will be followed by two additional shots at six and 12 months.
Dengvaxia vaccine's safety and effectiveness has been assessed in three randomised and placebo-controlled studies involving around 35,000 individuals in dengue-endemic areas such as Puerto Rico, Latin America and the Asia Pacific region.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV